Inventiva, a biopharmaceutical company developing oral therapy for metabolic dysfunction-associated steatohepatitis (MASH), announced its CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3. The company is currently conducting a pivotal Phase 3 clinical trial for its drug lanifibranor targeting MASH, a chronic liver disease. This presentation offers Inventiva a platform to update investors and stakeholders on its progress and future plans. Additional individual meetings will also be held during the conference.
LiquidStack, a Trane Technologies company, has commercially launched its GigaModular™ CDU platform designed for high-density AI data centers. The platform offers flexible, scalable liquid cooling capacity up to 14 MW, enabling operators to expand coo...
Electrolux Group has announced a fully underwritten rights issue of approximately SEK 9.06 billion, subject to approval at an Extraordinary General Meeting on May 27, 2026. The proceeds will finance growth initiatives, including a strategic partnersh...
XRP has experienced renewed volatility this week, trading between $1.35 and $1.55, driven by speculation around ETF activity and institutional interest, including mentions of Goldman Sachs. Regulatory progress with the U.S. CLARITY Act has added opti...
Private equity firms Bain Capital, Warburg Pincus, and Blackstone are considering bids to take Nikkon Holdings private in a deal potentially worth up to $7 billion. Nikkon Holdings, a Tokyo Stock Exchange-listed logistics company with a market cap ar...
Metallium Limited presented its patented Flash Joule Heating (FJH) technology at the Canaccord Genuity Global Metals and Mining Conference, highlighting its potential to revolutionize metals processing and reduce U.S. dependence on China. The technol...
